While the Rife Digital Professional V3 on the Dental program can assist with many issues, especially periodontal related disease, it cannot grow teeth or regrow teeth?
A Japanese biotechnology company called Toregem Biopharma Co., Ltd., based in Kyoto Japan, is leading the development of a groundbreaking drug designed to regrow human teeth. The research is being spearheaded by Dr. Katsu Takahashi, a dentist and researcher at Kitano Hospital in Osaka, who has spent years studying the genetic and molecular mechanisms behind tooth development. The drug works by inhibiting a protein known as USAG-1 (Uterine Sensitization–Associated Gene-1), which naturally suppresses tooth growth. By blocking this protein, scientists have successfully triggered the growth of new teeth in animal models such as mice and ferrets — a world first in regenerative dental medicine.
Toregem Biopharma’s researchers believe the technology restores teeth for people who have lost teeth due to decay, gum disease, or injury. The company has begun early-stage human clinical trials to test the drug’s safety and effectiveness, with initial results expected in the coming years. If successful, the therapy could be available for clinical use around 2030.
While still experimental, this development represents a major advance in regenerative medicine — offering hope that one day, humans might be able to naturally regrow lost teeth rather than relying on implants or dentures.
